isosorbide mononitrate | Monochinque retard capsules retard 50 mg, 30 pcs.
Special Price
$20.37
Regular Price
$28.00
In stock
SKU
BID494323
Latin name
MONOCINQUEВ® RETARD
MONOCINQUEВ® RETARD
Latin name
MONOCINQUEВ® RETARD
Release form
Retard capsules.
packaging 30 pcs
Pharmacological action
Pharmacodynamics
Peripheral vasodilator with a primary effect on venous vessels. Antianginal drug.
Reduces preload (due to the expansion of peripheral veins) and afterload (due to a decrease in OPSS), reduces myocardial oxygen demand.
Expands coronary arteries and improves coronary blood flow, promotes its redistribution to ischemic areas, reduces the final diastolic volume of the left ventricle and reduces the systolic tension of its walls. Increases exercise tolerance in patients with coronary heart disease, reduces pressure in the pulmonary circulation.
At the molecular level, it acts due to the formation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), a decrease in the concentration of calcium in smooth muscle cells.
The special dosage form of Monochincve® retard with a slow release of the active substance provides a therapeutic concentration of the drug in the blood within 24 hours after taking a single daily dose.
The drug is recommended for long-term therapy.
Pharmacokinetics
Absorption and metabolism
After oral administration, isosorbide-5-mononitrate is rapidly and completely absorbed from the gastrointestinal tract. The bioavailability of the drug when administered is from 90 to 100%. Cmax in blood plasma is reached after 1-1.5 hours after administration.
Not exposed to first pass through liver.
Excretion of
Isosorbide-5-mononitrate is excreted by the kidneys exclusively in the form of metabolites. Approximately 2% is excreted unchanged.
T1 / 2 is approximately 5 hours, which is approximately 8 times higher than that of isosorbide dinitrate.
Indications
Prevention and long-term therapy of angina pectoris of the III-IV functional classes
rehabilitation treatment after myocardial infarction
treatment of chronic heart failure (as part of combination therapy).
Contraindications
Hypersensitivity to organic nitrates
acute circulatory disorders (shock, vascular collapse)
hemorrhagic stroke
acute stage of myocardial infarction
concurrent use of inhibitors of sphylodenyl arteriolysis (90) diastolic blood pressure <60 mm RT. Art.)
state after traumatic brain injury
angle-closure glaucoma
glucose-6-phosphate dehydrogenase deficiency
age under 18 years.
Use during pregnancy and lactation
During pregnancy, the drug can be prescribed only for strict indications, when the expected therapeutic effect for the mother outweighs the potential risk to the fetus.
If there is a need to use the drug during lactation, then breastfeeding must be stopped.
Composition
1 capsule contains:
50 mg active sorblit:
Excipients:
sucrose,
corn starch,
ethyl cellulose,
stearic acid,
talc,
dye red 4R (E124),
quinoline yellow (E104),
titanium dioxide, gelatin.
Dosage and administration of
Monochincve® retard is prescribed 50 mg (1 caps.) 1 time / day in the morning after meals, without chewing and drinking with a small amount of liquid.
Dose should be adjusted depending on the condition of the patient.
Side effects
When taking Monochinque® Retard in the recommended dose, the side effects are not described.
However, as with the use of other nitrates, it is possible:
From the cardiovascular system: at the beginning of treatment - a nitrate headache, which usually decreases after a few days after continuing therapy after the first dose or after increasing the dose - arterial (i.e. h orthostatic) hypotension, accompanied by tachycardia, dizziness, weakness.
From the digestive system: very rarely - nausea, vomiting.
Dermatological reactions: very rarely - redness of the face and skin allergic reactions.
Drug Interaction
When co-administered with Wobenzim with other medicinal products, incompatibilities are unknown. diuretics, muscle relaxants, glucocorticosteroids, insulin reduce the effect of the drug.
Magnesium should be used with caution if you are taking magnesium-containing drugs, such as antacids or laxatives, or potassium-sparing diuretics or medicines containing calcium. When used simultaneously with drugs containing aluminum, the absorption of aluminum in the body can be increased.
Magnesium should be used with caution when used with digitalis preparations, since simultaneous use may impair the absorption of digitalis preparations.
Some antibiotics (aminoglycosides), cisplatin and cyclosporin A may lead to increased magnesium excretion.
Some diuretics (thiazides and furosemide), cetuximab and erlotinib, sildenafil, ethanol may potentiate the antihypertensive effect of Monochinkwe® retard.
Overdose
No cases of overdose have been reported.
However, if symptoms of overdose occur, the usual measures are recommended: to induce vomiting, to wash the stomach.
It is necessary to monitor whether the patient has taken any other medicines at the same time, to monitor the parameters of hemodynamics.
Storage conditions
Store in a dark place, out of the reach of children, at a temperature not exceeding 25 РC.
Expiration
3 years.
The active substance
Isosorbide mononitrate
pharmacy terms for
dosage form
dosage form
capsules depot
Berlin-Chemie / Menarini Germany
MONOCINQUEВ® RETARD
Release form
Retard capsules.
packaging 30 pcs
Pharmacological action
Pharmacodynamics
Peripheral vasodilator with a primary effect on venous vessels. Antianginal drug.
Reduces preload (due to the expansion of peripheral veins) and afterload (due to a decrease in OPSS), reduces myocardial oxygen demand.
Expands coronary arteries and improves coronary blood flow, promotes its redistribution to ischemic areas, reduces the final diastolic volume of the left ventricle and reduces the systolic tension of its walls. Increases exercise tolerance in patients with coronary heart disease, reduces pressure in the pulmonary circulation.
At the molecular level, it acts due to the formation of nitric oxide (NO) and cyclic guanosine monophosphate (cGMP), a decrease in the concentration of calcium in smooth muscle cells.
The special dosage form of Monochincve® retard with a slow release of the active substance provides a therapeutic concentration of the drug in the blood within 24 hours after taking a single daily dose.
The drug is recommended for long-term therapy.
Pharmacokinetics
Absorption and metabolism
After oral administration, isosorbide-5-mononitrate is rapidly and completely absorbed from the gastrointestinal tract. The bioavailability of the drug when administered is from 90 to 100%. Cmax in blood plasma is reached after 1-1.5 hours after administration.
Not exposed to first pass through liver.
Excretion of
Isosorbide-5-mononitrate is excreted by the kidneys exclusively in the form of metabolites. Approximately 2% is excreted unchanged.
T1 / 2 is approximately 5 hours, which is approximately 8 times higher than that of isosorbide dinitrate.
Indications
Prevention and long-term therapy of angina pectoris of the III-IV functional classes
rehabilitation treatment after myocardial infarction
treatment of chronic heart failure (as part of combination therapy).
Contraindications
Hypersensitivity to organic nitrates
acute circulatory disorders (shock, vascular collapse)
hemorrhagic stroke
acute stage of myocardial infarction
concurrent use of inhibitors of sphylodenyl arteriolysis (90) diastolic blood pressure <60 mm RT. Art.)
state after traumatic brain injury
angle-closure glaucoma
glucose-6-phosphate dehydrogenase deficiency
age under 18 years.
Use during pregnancy and lactation
During pregnancy, the drug can be prescribed only for strict indications, when the expected therapeutic effect for the mother outweighs the potential risk to the fetus.
If there is a need to use the drug during lactation, then breastfeeding must be stopped.
Composition
1 capsule contains:
50 mg active sorblit:
Excipients:
sucrose,
corn starch,
ethyl cellulose,
stearic acid,
talc,
dye red 4R (E124),
quinoline yellow (E104),
titanium dioxide, gelatin.
Dosage and administration of
Monochincve® retard is prescribed 50 mg (1 caps.) 1 time / day in the morning after meals, without chewing and drinking with a small amount of liquid.
Dose should be adjusted depending on the condition of the patient.
Side effects
When taking Monochinque® Retard in the recommended dose, the side effects are not described.
However, as with the use of other nitrates, it is possible:
From the cardiovascular system: at the beginning of treatment - a nitrate headache, which usually decreases after a few days after continuing therapy after the first dose or after increasing the dose - arterial (i.e. h orthostatic) hypotension, accompanied by tachycardia, dizziness, weakness.
From the digestive system: very rarely - nausea, vomiting.
Dermatological reactions: very rarely - redness of the face and skin allergic reactions.
Drug Interaction
When co-administered with Wobenzim with other medicinal products, incompatibilities are unknown. diuretics, muscle relaxants, glucocorticosteroids, insulin reduce the effect of the drug.
Magnesium should be used with caution if you are taking magnesium-containing drugs, such as antacids or laxatives, or potassium-sparing diuretics or medicines containing calcium. When used simultaneously with drugs containing aluminum, the absorption of aluminum in the body can be increased.
Magnesium should be used with caution when used with digitalis preparations, since simultaneous use may impair the absorption of digitalis preparations.
Some antibiotics (aminoglycosides), cisplatin and cyclosporin A may lead to increased magnesium excretion.
Some diuretics (thiazides and furosemide), cetuximab and erlotinib, sildenafil, ethanol may potentiate the antihypertensive effect of Monochinkwe® retard.
Overdose
No cases of overdose have been reported.
However, if symptoms of overdose occur, the usual measures are recommended: to induce vomiting, to wash the stomach.
It is necessary to monitor whether the patient has taken any other medicines at the same time, to monitor the parameters of hemodynamics.
Storage conditions
Store in a dark place, out of the reach of children, at a temperature not exceeding 25 РC.
Expiration
3 years.
The active substance
Isosorbide mononitrate
pharmacy terms for
dosage form
dosage form
capsules depot
Berlin-Chemie / Menarini Germany
Submit your review to Earn 10 Reward Points click here to login
Write Your Own Review